“At least 5 billion people live in countries where there is limited or no availability of opioids for pain treatment,”

“At least 5 billion people live in countries where there is limited or no availability of opioids for pain treatment,”

https://www.theguardian.com/society/2019/sep/18/us-attack-world-health-organization-who-hindering-morphine-drive-poor-countries

An attack on the World Health Organization (WHO) by US politicians accusing it of being corrupted by drug companies is making it even more difficult to get morphine to millions of people dying in acute pain in poor countries, say experts in the field.

Representatives of the hospice and palliative care community said they were stunned by the Congress members’ report, which they said made false accusations and would affect people suffering in countries where almost no opioids were available.

“At least 5 billion people live in countries where there is limited or no availability of opioids for pain treatment,” according to the International Association for Hospice and Palliative Care (IAHCP). More than 18 million people a year worldwide die with “untreated, excruciating pain”, the organisation says.

The report by the Democratic congresswoman Katherine Clark and the Republican congressman Hal Rogers, published in May, has undermined efforts to encourage governments to buy generic morphine or other appropriate opioids and doctors to prescribe them, dealing a severe blow to the struggle to help people dying in acute pain from cancer, Aids, injuries and other conditions, the IAHPC says.

The palliative care experts say low- and middle-income countries need cheap morphine, not patented opioid drugs such as OxyContin, at the centre of the US opioids crisis.

According to the UN’s International Narcotics Control Board (INCB), only 10% of the world’s morphine is used for palliative care. Almost all of the remainder is converted into codeine and used in cough medicine for sale in wealthy nations. “That makes it difficult for countries with fewer resources to procure any of the limited amount of morphine available for palliative care,” said a 2018 INCB report on access to controlled drugs for medical use.

There is anxiety in many countries about the potential for opioid addiction, which has been heightened by events in the US.

The Congress members accused WHO and the palliative care community of being influenced by funding from Purdue Pharma, the company accused of precipitating the disaster in the US. Two sets of WHO guidelines on the prescribing of opioids wrongly claim the drugs are safe, says the report, supporting Purdue’s claim that dependence occurs in less than 1% of patients and talking of the need to tackle “opiophobia”, which stops doctors prescribing the medications.

Congresswomen Katherine Clark

 

Congresswomen Katherine Clark. Photograph: Joseph Prezioso/AFP/Getty Images

“The web of influence we uncovered, combined with the WHO’s recommendations, paints a picture of a public health organisation that has been manipulated by the opioid industry,” says the Congress members’ report.

WHO and palliative care organisations have denied taking money or being influenced by Purdue Pharma’s global offshoot, Mundipharma. But the decision of WHO to withdraw the guidelines immediately after the criticism dismayed the palliative care community. The move will further discourage countries from trying to buy the drugs, they say.

Dr Lukas Radbruch, the chair of the IAHPC, said the opioid crisis in the US had caused global alarm before the attack on WHO. “Stakeholders are getting more reluctant to advocate for easy access to opioids,” he said, citing India as one of the countries that had slowed down. He said he had seen morphine locked in a small safe labelled “poisonous drugs cupboard” in one of the largest hospitals in the world, in Johannesburg. In sub-Saharan Africa, people still die in agony as a result of Aids.

“We were really shocked about the withdrawal of the guidelines from WHO in response to that report,” said Radbruch, a professor of palliative medicine at the University of Bonn. The two sets of guidelines, from 2011 and 2012 – Ensuring Balance in National Policies on Controlled Substances, and Guidelines on the Pharmacological Treatment of Persisting Pain in Children with Medical Illnesses – provided vital information and guidance to governments and doctors on what was safe and necessary for pain relief.

“This wasn’t influenced by any of the pharmaceutical companies,” said Radbruch, who was involved in drawing up the guidelines. The IAHPC, which was also attacked in the report, has published a detailed refutation of the allegations, saying claims it took pharma money are false. “The IAHPC has never served the interests of Purdue or any other pharmaceutical company to influence WHO or any other agency, government, institution or entity,” it says.

Prof Felicia Knaul of the University of Miami, chair of a recent Lancet commission on palliative care, said the Congress members’ report was not evidence-based. “Actions that are not based in evidence will do harm,” she said.

The stakes were high, she said. “I believe that policies that work to deny access to necessary pain relief medication in low- and middle-income countries because of the situation in the United States are akin to denying food to people suffering from malnutrition because there is an obesity epidemic in the United States.

“More than 60 million people every year require pain relief and palliative care and we know that more than 80% get virtually nothing. The vast majority of those individuals live in low- and middle-income countries. I consider it despicable from an ethical point of view and completely antithetical to the goals of global health and sustainable development to have children and adults living and dying in extreme pain when we have very inexpensive safe medications that we could offer them. Poor policies in the United States are not an excuse for allowing that to continue to happen.”

Clark said in a statement that “all patients deserve access to the medical care they need to live with dignity and without pain, and that includes access to medically appropriate pain medication”. But opioid manufacturers including Purdue Pharma had lied about the risk of substance use disorder and their claims made their way into the WHO guidelines, she said.

“Some critics, including those financed by the opioid industry, would have you believe that we face a choice between irresponsibly flooding countries with powerful opioids or leaving patients to suffer without any pain relief at all. This is simply not true,” said Clark.

An electric syringe pump administering morphine in Congo-Brazzaville
An electric syringe pump administering morphine in Congo-Brazzaville. Photograph: Alamy

“No one disagrees that patients deserve access to medically appropriate treatment, but they also deserve factually accurate information about the care they receive and the risks that they might face. In addition, respected health authorities have a responsibility to promote appropriate access to palliative care while at the same time working to prevent the opioid crisis that we are experiencing in the United States from being replicated across the globe.”

A spokesperson for Rogers said he and Clark had raised legitimate concerns with WHO in 2017 that Purdue Pharma’s “reckless and unsavoury marketing strategies” would be employed internationally and lead to a global crisis.

“Their goal has never been to restrict access to therapies for patients truly in need of palliative or other care,” the spokesperson said of the Congress members. “In fact, he [Rogers] agrees that WHO ought to ‘ensure adequate access to internationally controlled essential medicines necessary for the relief of suffering, while preventing diversion and non-medical use’.

“However, it is clear that in the United States, we have failed to prevent vulnerable patients from [unwittingly becoming addicted] to powerful pain medications – and that is due in large part to the influence of companies like Purdue Pharma that put profit above people.

“Unless and until organisations like the World Health Organization do more to ensure that the pharmaceutical industry does not unduly influence their policy-making, these patients remain at risk.”

Mariângela Simão, a WHO assistant director general in charge of access to medicines, said: “WHO pushes for a balanced approach – people suffering severe pain should get the medication they need. At the same time, some pain medication, specifically opioids, needs careful handling through sound prescription practices and regulations to reduce the risk of abuse and potential harm.

“WHO withdrew the 2011 and 2012 guidelines because new evidence on these risks has come out in recent years and, on examination, they were not fully aligned with revised internal procedures. We are now in the process of reviewing the guidelines for publication next year.”

The world population is abt 8 BILLION and if 65% of the world’s population has no access to pain management… it is little wonder that some anti-opiates can claim that the USA consumes the majority of the world’s opiate production. Because 65% of the world’s chronic pain pts are allowed to live – or die – in a torturous level of pain.

And according to this article our CONGRESS is not helping the problem at all… and .. apparently doing just the opposite…

 

Medication mix-up at CVS Pharmacy lands teen in emergency room

Medication mix-up lands teen in emergency room

https://www.wfsb.com/news/medication-mix-up-lands-teen-in-emergency-room/article_af8d05b0-e942-11e9-8d3f-7f83e7a8fcd4.html

SOUTHINGTON, CT (WFSB) — A Southington teen was hospitalized recently after she took the wrong prescription pills because of a medication mix-up by her local pharmacy.

Alyssa Watrous, 17, had recently felt strange after picking up her prescription for asthma medication at a CVS pharmacy in Southington.

“Just throughout the day on Friday I didn’t feel good because I was feeling all the side effects,” Alyssa Watrous said.

“She had side effects from it such as nausea weakness dizziness pounding headache,” her mom Jill Watrous said.

After taking the pills from CVS for two days, Alyssa realized there had been a terrible mix up.

“She called me, ‘mom, mom there’s somebody else’s name on my medicine’,” Jill Watrous said.

It turns out, Alyssa had been taking blood pressure medication instead of her asthma pills.

CVS had accidentally given Alyssa the wrong prescription and she had been taking a lot of it.

Commonly for the medication she had, you’d take one pill a day for an adult and she was taking three at a time, because she was following the directions for her medication.

Jill Watrous called CVS and poison control right away. They said Alyssa had technically overdosed on the blood pressure pills and should go to the emergency room.

Fortunately, doctors told Alyssa she had come in just in time to avoid serious problems.

“They said thank goodness, there wouldn’t be any long-term effects, that it’s something will leave your system,” Alyssa Watrous said.

In a statement, CVS admitted to the error saying “We sincerely apologize to Ms. Watrous and her family. Prescription errors are a very rare occurrence, but if one does happen, we do everything we can to learn from it in order to continuously improve quality and patient safety.”

Jill appreciates the apology but says the CVS’ mix-up has taught her family a valuable lesson.

“I just think it’s important for people not to take for granted that the pharmacies always doing the right thing and that they don’t make mistakes, because clearly it happens,” she said.

From now on, the Watrous family says they will be even more diligent by checking the information on the bottle is accurate and even looking up pictures of the correct pill to make sure they are taking the right medication.

Cartoon: DEA is a poor lifeguard

https://www.standard.net/opinion/cartoons/cartoon-dea-is-a-poor-lifeguard/image_ec97997b-edb0-5bc9-99ec-733ae6b74802.html

Designing A New Class Of Drugs To Treat Chronic Pain

Designing A New Class Of Drugs To Treat Chronic Pain

https://www.news-line.com/PH_news29664_enews

A UC Davis research team, led by Vladimir Yarov-Yarovoy and Heike Wulff, will receive a $1.5 million grant from the National Institutes of Health (NIH) to develop a novel class of peptides that are better at treating pain and don’t have the side effects of opioids. The grant is part of the NIH initiative Helping to End Addiction Long-Term (HEAL Initiative).

“With the national opioid crisis, we more than ever need a safer, more effective and non-addictive class of medications to treat chronic pain,” said Vladimir Yarov-Yarovoy, associate professor of physiology and membrane biology at UC Davis School of Medicine and principal investigator of the study.

“Dr. Yarov-Yarovoy is leading the next wave of innovative and novel therapeutics for pain,” said David Copenhaver, associate professor and Chief of the Pain Medicine Division at UC Davis. “We are excited to collaborate on this journey of discovery to find novel, safe and effective agents to treat pain.”

Scott Fishman, professor and director of UC Davis Center for Advancing Pain Relief, agrees.

“Receiving this grant reflects the great potential for this work to help millions of people in pain,” Fishman said. “We look forward to bringing this exciting science to the front lines of patient care.”

Targeting specific sodium channels

Previous research has identified voltage-gated sodium ion channels, especially NaV1.7, NaV1.8 and NaV1.9, as critical elements in pain signaling and transmission.

Certain peptides, such as the tarantula-based toxin ProTx-II, are known to block specific sodium channels, preventing nerve cells from transmitting signals that trigger pain.

“We want to relieve pain without the side effect of addiction that occurs with opioids,” said Karen Wagner, a co-investigator who studies pain in animal models.

“By targeting the relevant sodium channels instead of the receptors usually targeted by opioids, we provide an alternative to the addictive and detrimental effects of opioid pain medications.”

Blocking sodium channels to control pain

To ultimately relieve chronic pain, the researchers want to identify the most effective peptide design that can block the relevant sodium channels without affecting the activity of other channels.

In January 2019, several high-resolution structures of human sodium channel were published, giving the researchers a better understanding of the interactions between peptides and the sodium channels. Using the computational power of Rosetta software, the UC Davis researchers will design and synthesize different versions of the ProTx-II-based peptide to identify those that best selectively and effectively block pain-associated channels.

“Starting from the naturally-occurring ProTx-II peptide, we can improve the design of these toxins by optimizing for potency and selectivity,” said Wulff, a professor of pharmacology and director of the Probe and Pharmaceutical Optimization core of the UC Davis CounterACT Center of Excellence. “We will trim ProTx-II down to its essential binding parts to enhance its targeting of specific pain-related channels.”

Designed peptides that are found to selectively block voltage-gated sodium ion channels will be sent to Jon Sack’s laboratory for testing on neurons. Based on this testing, the researchers will choose the peptides that would be used in animal models.

The NIH launched the HEAL Initiative in April 2018 to improve prevention and treatment strategies for opioid misuse and addiction and enhance pain management.

“It’s clear that a multipronged scientific approach is needed to reduce the risks of opioids, accelerate development of effective non-opioid therapies for pain and provide more flexible and effective options for treating addiction to opioids,” said NIH Director Francis Collins.

The Team

Yarov-Yarovoy is an expert in computational modeling of peptide toxin – ion channel interactions and peptide design targeting ion channels.

Heike Wulff specializes in preclinical therapeutics development targeting ion channels and has developed an ion channel-targeted peptide toxin variant currently in clinical trials.

Bruce Hammock, a distinguished professor of entomology and director of the NIEHS-UCD Superfund Research Program, conducts research to develop preclinical therapeutics to control acute and neuropathic pain.

Karen Wagner, a research scientist in the Department of Entomology, researches neurobiology of inflammation, pain and chronic neurodegenerative diseases.

Jon Sack, an associate professor of physiology and membrane biology, specializes in mechanisms of voltage-gated ion channel modulation by toxins, and the design of novel probes to monitor ion channel activity.

Daniel Tancredi is a biostatistician and associate professor of pediatrics at UC Davis School of Medicine.

Project title: Optimization of non-addictive biologics to target sodium channels involved in pain signaling.

The Pharmas generally spends upward to 500 million dollars on R&D to discover a new medication… and … The National Institute of Health is providing a 1.5 MILLION grant to fund a new pain medication discovery ?

We have already been down this path of a non-addicting pain medicine… one was Stadol and one was Talwin and both ended up being abused and being made a controlled substances.

Then we have the whole class of NSAID ( Aspirin, Motrin , Aleve ) and while they are now OTC… it is claimed that 15,000 people die every year from the use/abuse of this class of drug… mostly from intestinal bleeds.

I am neither going to hold my breath or bet the farm that this research will bring out a non-addicting pain medication

Could we solve GLOBAL WARMING AND OUR NATIONAL DEBT CRISIS using GENOCIDE ?

Just think about it… global warming is blamed on excessive CO2… along with other things like COW FARTS ( Methane )

Every time that one of us exhales… we expel CO2…  fewer people would mean less CO2 and it would probably mean fewer cows… since fewer people would suggest fewer steak/hamburgers being consumed and thus less cow farts.  Fewer people driving/traveling less miles in various means of transportation all contributing to increased CO2

Then we have all those disabled/handicapped/medically compromised pts that many refer to as “takers” because they take more from our society than they contribute…

We really can’t go out and “knock people off”, but if we limit or compromise their medical treatment so that their co-morbidity issues to escalate or worsen and they die of “natural causes”

The millions of dollars that our country could save from fewer Medicare/Medicaid pts that have to receive treatment could help address our 22 trillion national debt and extent the years of viability of the Medicare and SS trust funds could be substantial. Insurance companies could either become more profitable or reduce the premium costs .. since fewer people needing expensive medical care.

Could the chronic pain community be the “guinea pigs” to see if such a theory could work… since most chronic pain pts are having their therapy limited and many are choosing suicide as the final solution to end their pain and many are dying of “natural causes” because their untreated pain is causing their other health issues to worsen

 

Flu vaccine selections may be an ominous sign for this winter

Flu vaccine selections may be an ominous sign for this winter

https://www.statnews.com/2019/09/30/flu-vaccine-selections-may-be-an-ominous-sign-for-this-winter/

It’s never an easy business to predict which flu viruses will make people sick the following winter. And there’s reason to believe two of the four choices made last winter for this upcoming season’s vaccine could be off the mark.

Twice a year influenza experts meet at the World Health Organization to pore over surveillance data provided by countries around the world to try to predict which strains are becoming the most dominant. The Northern Hemisphere strain selection meeting is held in late February; the Southern Hemisphere meeting occurs in late September.

The selections that officials made last week for the next Southern Hemisphere vaccine suggest that two of four viruses in the Northern Hemisphere vaccine that doctors and pharmacies are now pressing people to get may not be optimally protective this winter. Those two are influenza A/H3N2 and the influenza B/Victoria virus.

The strain selection committee concluded the H3N2 and B/Victoria viruses needed to be updated because the ones used in the Northern Hemisphere vaccine didn’t match the strains of those viruses that are now dominant. Influenza epidemiologist Dr. Danuta Skowronski described the significance of those two changes in one word: “mismatch.”

“I think the vaccine strain selections by the WHO committee are obviously important for the Southern Hemisphere but they’re also signals to us because they’re basing their decisions on what they see current predominating on the global level,” said Skowronski, who is with the British Columbia Center for Disease Control in Vancouver.

Scott Hensley, an associate professor of microbiology at the University of Pennsylvania, agreed. But Hensley cautioned that at this point it’s too soon to know what versions of the viruses will be circulating. And even if there is a mismatch, its impact may be not be massive, depending on which viruses are causing the most illness this winter.

“There are many ways that this flu season may pan out,” Hensley said. “For example, we’ve had a lot of H3N2 [activity] the last few years. So it’s possible that this flu season in the Northern Hemisphere will be dominated by H1N1 viruses. And if that’s the case we think that the H1N1 antigens [in the vaccine] are very well matched with the types of H1N1 viruses that are circulating right now.”

Flu vaccine is a four-in-one or a three-in-one shot that protects against both influenza A viruses — H3N2 and H1N1 — and either both or one of the influenza B viruses, B/Victoria and B/Yamagata. Most flu vaccine is made with killed viruses, and most vaccine used in the United States is quadrivalent — four-in-one.

There was great uncertainty around which version of H3N2 to choose for the Northern Hemisphere vaccine when the committee met last February — there was a lot of variation between the strain the U.S. was seeing and the H3N2 viruses sickening people in Canada and Europe. There was so much uncertainty, in fact, that the committee delayed making the choice of the H3N2 strain for a month to try to get a clearer picture.

In the end, the committee selected a version of the virus that was causing a wave of late season illness in the United States. (Canada also had a late season surge of H3N2 activity, but caused by a different version of the virus.)

“That H3N2 wave was late and it was evolving at the time that they met in February,” Skowronski said of the strain selection committee. “And there was a diverse mix of H3 viruses. And it wasn’t clear to them, I guess, [which strain] … would emerge the clear winner.”

It appears the virus that was ultimately selected is not the H3N2 that dominated during the Southern Hemisphere’s winter 2019 season.

Hensley said the variant of H3N2 viruses that just swept through the Southern Hemisphere is more likely to be the main cause of H3N2 infections for the Northern Hemisphere this winter than was the case in the U.S. late last winter and into the early spring.

But that version of H3N2 is difficult to grow in eggs, which is the way the vast majority of flu vaccines is made, he noted, suggesting that fact may have influenced the thinking of the selection committee last March.

In recent years the H3N2 component has generally been the least effective part of the vaccine. If H3N2 viruses predominate this coming flu season, a vaccine mismatch could add to the severity of the season. But if those viruses play a smaller role this winter, the impact of a mismatch will be less significant, making it hard to predict if this choice is going to turn out to be a problem.

Flu circulation “remains difficult to predict and flu viruses are constantly breaking rules that we try to establish for them,” Hensley said, adding that flu vaccines “often protect against severe disease even when … mismatched.”

The selection of a new B/Victoria virus for the Southern Hemisphere 2020 shot also concerns Skowronski. There was almost no influenza B activity in the 2018-2019 flu season and it’s been several years since B/Victoria viruses have caused much illness. As a result, there may not be a lot of immunity to those viruses in the population, she said.

B/Victoria flu viruses are especially hard on children, Skowronski said.

Given the possibility that a couple of the components of the vaccine might not be well-matched to circulating flu viruses, Skowronski said it will be important for doctors to realize vaccinated patients may still contract influenza. For those who are at high risk of developing severe illness, rapid treatment with flu antiviral drugs should be considered.

She also suggested older people or people who have underlying health problems — in other words, those who are likely to develop a severe case of flu if they contract the virus — should take steps to avoid being around sick people.

The sliver of good news: The officials meeting at the WHO last week concluded that the H1N1 and the flu B/Yamagata components of the Southern Hemisphere vaccine didn’t need to change, suggesting they are representative of the strains of those viruses we’re likely to encounter this winter.

 

Majority of rule making by HHS & FDA declared UNCONSTITUTIONAL

FULL_HHS_report_DIGITAL[23782]

Opioid patient ‘at a loss’ after prescriber’s suspension

Opioid patient ‘at a loss’ after prescriber’s suspension

https://fox17online.com/2019/05/10/opioid-patient-at-a-loss-with-prescribers-suspension/

NORTON SHORES, Mich. — Bonnie Drier said a state investigation into her nurse practitioner, Susan Drust, caught her by surprise.

“To hear what they’re saying, I don’t understand it because she was forthright, and she was always there when I needed her,” Drier said.

Drust, who runs a clinic in Norton Shores, is accused of prescribing controlled substances to alcoholics, allegedly prescribing unsafe combinations of opioids and/or sedatives without documenting the risk or reason. The state claims she didn’t document any consideration of alternate treatments outside of opioids.

So the state suspended her license and clinic operations.

Drier said she thought, “Oh my God, what am I supposed to do?”

The Norton Shores resident said she’s depended on Drust to prescribe her fentanyl patches monthly and says the nurse practitioner has been instrumental in decreasing that dependency.

“Susan helped me back down from 50 micrograms to 12.5 micrograms, and she did me a huge justice by doing that,” Drier said.

She said it’s progress following a failed back surgery in 2013. Now she’s concerned the loss of rapport with her healthcare provider poses a risk in safely managing her pain.

“Now I have to start it all over with a pain clinic,” Drier said.

She added, “Will I be able to go back to her for my regular stuff — my non-opioid stuff, my regular stuff? I’m terrified of trying to have to ween myself off when it’s dangerous to begin with.”

FOX 17 called the clinic, again, which had no further comment. It’s important to note the license suspension is only temporary for Drust. The state still needs to determine if she violated public health code. That’ll happen at a later date.

So much for innocent until proven guilty…this sounds like the state board will now go back and “draw up opinions” to validate their allegations,  find her guilty and revoke  her license and close the case.

At this point there appears to be NO ALLEGATIONS OF A “DEAD BODY” because of her prescribing.

Generally, the OPINIONS of those trying to prove their allegations is pretty fungible.  That is how WITCH HUNTS go !!!

I just wonder how many legit chronic pain pts will just be “thrown to the wolves ” with little/no concern of their health outcomes ?

should we all start paying with CASH and giving “false names” on “frequent buyer discount cards” ?

Does your doctor need to know what you buy on Amazon?

Brokers are selling your data to your doctor, and no one’s regulating it.

https://www.politico.com/amp/story/2018/10/30/the-doctor-will-see-through-you-now-893437

Google, Amazon, insurers and credit card companies have long been able to tell whether you vote, own a dog, spent time in prison or drive a rusty 1997 Chevrolet. Now, that type of information is starting to pop up in front of doctors when you walk into their examination rooms.

A small but fast-growing number of technology companies, including data brokers LexisNexis and Acxiom, sell health care providers detailed analyses of their patients, incorporating criminal records, online purchasing histories, retail loyalty programs and voter registration data.

Some health systems think the data may drive better medical decision-making — helping them identify patients at risk of expensive care or rehospitalization, for instance, and enabling them to connect hurting patients with follow-up care or social work programs. The fact that a hypertension patient lives in a food desert, or lacks carfare to get to appointments, may be more important to her health than any prescription written by a doctor, former AMA President David Barbe noted in an interview.

The medical profession increasingly recognizes that it needs to be aware of how socioeconomic context — the buzz phrase is “social determinants of health” — is vital to a patient’s whole health. The flip side of benevolent concern, however, could be pigeonholing or invasions of privacy.

There are few safeguards on how such outside information can be used within the health system. The algorithms that companies use to classify some patients as “high risk” are rarely made public, so patients may not know their purchasing history or lifestyle could catapult them into a higher-risk strata. For every health plan that uses algorithms to predict substance abuse and help patients get treatment, there could be one that turns patients away when it learns they have.

Federal law protects personal health information held within the healthcare system; it doesn’t stop doctors from using outside data to learn more about how their patients live. If Congress overturns the rest of the Affordable Care Act, as Sen. Mitch McConnell has suggested, health insurers could use a patient’s grocery purchases or internet browsing history, as the basis for charging a high premium.

Even if the law doesn’t change, “there is risk that people who have personal issues at home will not seek care because combining their health data and their lifestyle data may have downstream consequences to them” such as discrimination in access to care, insurance or employment, says Crowell and Moring partner Jodi Daniel, a former HHS policy leader.

Laws and regulations don’t apply

At the moment, there’s nothing the government can do about these data uses. The FTC can crack down on data brokers for unfair or deceptive practices, but many current uses aren’t legally defined as unfair or deceptive, an agency spokesperson said.

FTC and Congress are getting interested, however, in privacy legislation that might force data brokers to share their sources or require consumer consent before gathering their data. The Senate Commerce Committee has been holding hearings that Chairman John Thune said could lead to changes in federal privacy law.

A bill introduced in April by Sens. Amy Klobuchar and John Kennedy would give consumers the right to review data collected on them and to opt out of online data collection. The FTC has held its own hearings to assess whether it needs new enforcement capabilities.

Privacy and data experts increasingly think something needs to be done, and soon. “We should consider some baseline guardrails for use of data and how to protect individuals from unintended consequences,” said Daniel. “In the meantime, I believe patients should be offered the choice” to deny insurers and doctors access to information about their lifestyles.

New laws or regulations may be needed to protect people from discrimination in employment or insurance — the way the 2008 Genetic Information Non-Discrimination Act shelters patients who undergo genetic testing from discrimination by health insurers, Daniel said. Others have called for preemptive limits on what data brokers can do with what they collect.

“Information is being provided to disparate companies for specific purposes, and then it gets in the hands of data brokers and is repurposed for things that people could never have imagined,” says Natasha Duarte, a policy analyst with the Center for Democracy & Technology. Once the information has been collected and sold, tracing a particular data point back to its origin is almost impossible, she said.

Non-voters don’t take care of themselves

The data that brokers peddle to health care providers is often wrong. Even when it isn’t, its usefulness to medicine is debatable. A recent study of 90,000 patients at the Duke University Health System concluded that putting socioeconomic data into a patient’s electronic health record didn’t improve the system’s ability to predict ER visits or hospitalizations. Apparently, doctors can figure out whether the patient in front of them is in bad shape whether the cause is an empty refrigerator or a genetic mutation.

Brokers and traders in private data are secretive about how they collect and check it for accuracy, or who buys it and for how much money.

LexisNexis has been quietly marketing a product called Socioeconomic Health Attributes that takes data from “more than 10,000 sources of public and proprietary records” and matches it to individual patients. It’s not the kind of information that normally populates a patient’s medical record.

“Liens, evictions and felonies indicate that individual health may not be a priority,” according to a marketing pitch on the company’s website. Voter registration might be relevant as well because “[i]ndividuals showing engagement in their community may be more likely to engage in their own health.”

Another LexisNexis product, Patient Identity Intelligence, can “continually update patient records with the latest demographic information,” and uses socioeconomic data to “better predict [hospital] readmission compared to models that use only clinical data,” the site says.

“We have seen providers increasingly testing and using social determinants of health over the last year to help improve their predictive modeling and care management programs,” a LexisNexis spokesperson said in an email statement, calling those providers “early adopters.”

LexisNexis would not disclose the sources of its information or how it calculates the “health risk score” it peddles to health care providers. The company directed questions about provider use to the American Medical Association, where a puzzled spokesman said the AMA had no knowledge of the matter.

A disclaimer on the LexisNexis website notes that the data flowing into its Socioeconomic Health Attributes “may contain errors.” Data from public and commercial sources are “sometimes reported or entered inaccurately, processed poorly or incorrectly, and [are] generally not free from defect.”

LexisNexis competitor CentraForce has taken another tactic: instead of selling an individual patient’s data to health care providers, it buys up large volumes of de-identified consumer survey data that includes answers to questions about trust in the medical system or substance use, as well as demographic identifiers. Providers then use the software to match patients by their demographic similarity to one of the risk categories CentraForce has established through data crunching.

The technology helps providers focus on patients whose behaviors put them at greater risk of hospital readmission or treatment failure, said Steve Newman, CentraForce’s executive chairman. He said the platform has gained traction among insurers running Medicare Advantage plans, which can lose money if their patients use up high levels of health care dollars.

Newman thinks CentraForce’s profiles are often more accurate than what patients tell their doctors.

“We know that patients will tell people in white coats different stories from what they will tell an anonymous survey company,” Newman said. “I can tell [doctors] unequivocally that the precision and accuracy of what [patients] tell us is greater than what they tell you.”

Since it doesn’t rely on personal health information to assign risk profiles, the product doesn’t require patient consent, Newman said. The company recommends that doctors use the profile to gently bring up specific health risks, “rather than in some sort of confrontational way,” he said. The added context “makes the provider, whether it’s a nurse or a physician, seem a little bit smarter, a little bit more attuned to the patient.”

Nuggets of obscure data can add up to insights, the data wranglers say. For example, “pet ownership is correlated with better outcomes. … Dogs more than cats,” says CEO Kurt Waltenbaugh of Carrot Health, which works with health plans to produce patient risk scores by crunching together medical and public records. An increase in a patient’s online purchases might suggest social isolation or poor health, he said.

But while LexisNexis and CentraForce risks scores may be mimicking the kinds of snap judgments doctors already make when they size up patients, the difference is that behavior outside the medical system may now be influencing the doctors’ judgment.

Patients often aren’t aware their information is being traded. In addition, the information that pops up in the electronic health record may be wrong or not applicable to them, said Tom Tomlinson, a privacy expert at Michigan State University’s Center for Ethics and Humanities in the Life Sciences.

Generalizations about people who don’t vote “don’t tell me whether it’s true of the person in front of me,” Tomlinson said. “What the generalization does is make me presume, without giving the patient the opportunity to prove me wrong.”

Data broker Acxiom sells data and services to identify patients eligible for community and social services based on sources such as retail history and public records. It can make detailed predictions identifying people who are likely to live with smokers even if they do not smoke, for instance, said Heidi West, its vice president for health care.

In the future the company hopes to integrate its assessments into the patient’s digital health record, West said. When it does, she hopes patients will log into Acxiom’s site to ensure their profiles are accurate. Acxiom currently has no legal requirement to do so; by correcting the profiles, individuals would be improving the data’s value to Acxiom and its clients.

West emphasized that the company wants to sell this information to providers so they can connect patients to appropriate preventive services or better tailor care. “If it even starts to go down the path of underwriting, or anything punitive, we will walk away from it,” she said.

Salesforce’s provider customers are using the software, which can integrate with EHRs, to sort patients by demographic data, including zip code, ethnicity or primary language, to refer them to relevant community health programs. “It’s the same as knowing what people’s shopping experience is,” chief medical officer Joshua Newman told POLITICO. Some providers use the software to flag patients who could benefit from counseling programs.

This type of use case attracts some physicians to the outside data. The AMA’s Barbe calls it “augmented intelligence” that could help him be a “better partner” to patients. The AMA has a project to identify the social, economic and behavioral factors most helpful to physicians treating conditions such as diabetes.

“There’s a real moral distress in taking care of people and giving them empty recommendations about what they need to do when they go home,” said physician Stacy Lindau, who created a platform matching people to local services based on their demographic data.

Socioeconomic and behavioral health information has long been used by retailers to target advertisements and services to consumers, and more recently insurers have tapped into similar data sources to flag high-risk patients. ProPublica and NPR reported on insurers partnering with data brokers to learn more about their clients’ health based on information found in the public domain.

Some data brokers have even lobbied to update HIPAA; the Claim Your Own Health Data Coalition, whose members include Experian, supported legislation to give data clearinghouses access to personal health information. The brokers say this would let them combine health data with other information and present detailed health analyses to patients, or de-identify those analyses and sell them to payers.

Digital health vendors hesitant

Cerner and Epic, the two largest electronic health records vendors, do not appear interested in incorporating background checks or detailed socio-behavioral profiles directly into their records, although they are starting to electronically connect patient records with community-based service providers.

Epic’s new release, for instance, can flag patients who might have transportation or food security issues. The company is piloting a product with researchers at the University of Wisconsin at Madison that could give clinicians detailed information about a patient’s neighborhood as part of its “precision patient engagement,” strategy, said Emily Barey, Epic’s vice president of nursing and community health.

Cerner’s vice president of population health, Marc Overhage, said the company focuses on patient-reported data, prompting patients to answer questions about their socioeconomic background when they log into their patient portals. That information can also be incorporated into scheduling systems so administrators can ask patients likely to have transportation issues if they need a ride to their appointment, for instance.

Some hospital systems, such as Providence St. Joseph Health, are testing the waters by putting basic data about income level, zip code, and food availability into patient records. But Rhonda Medows, who leads the population health team at the Washington-based system, said she has declined offers from data brokers who offer information from police records. It might be useful to know if the patient has suffered domestic violence, or a child has been at risk, but she can ask for that information from the patient.

“I’d rather have that dialogue [instead of] the police report,” she said. She doesn’t want “people to feel paranoid about tracking.”

And the idea a doctor can know things about your life outside the clinic that you haven’t told anyone else violates patient privacy and may damage trust in medicine, say critics.

If providers are only looking at cumulative risk scores, and they’re only used to “stratify people and target efforts to address social needs or impact social determinants of health on a personal or public health level, great,” said Karen DeSalvo, the former assistant secretary of health and national coordinator for health IT.

“Right now, given that ACA is still the law of the land, that data can’t be used to exclude people from coverage,” DeSalvo said said. “It gets dicey if that changes.”

Why do charge cards give people rebates for using their charge card ?  Why does a large number of retailers give you a discounted prices because you sign up for one of their frequent buyer cards ?  Should we use our real names when we subscribe to magazines or other things ?

How many/much of all these “data points” about you and your purchases being amassed , sorted and sold to various entities.

You are not required to give your legal name when signing up for these retail discount cards, or subscribe to magazine… should we being paid CASH for as many purchases as possible ?

Use cash to purchase Visa/MC/Amex/Discover cash card… and use that to make purchases anonymously.  There are numerous ways to “scramble” all the data points about you and/or your family.

Do we really want your healthcare professional to have access that you routinely purchase liquor/beer, tobacco or have a diet high in saturated fats and meat/professed meats ?

Get a VPN (virtual private network) to surf the web anonymously..  There are numerous ways to hide your real identity and there is nothing illegal about it.

Breath test detects opioids

Breath test detects opioids

https://physicsworld.com/a/breath-test-detects-opioids/

A test to detect opioid drugs in exhaled breath has been developed by engineers and physicians at the University of California, Davis. Such a breath test could be useful in caring for chronic pain patients, as well as for checking for illegal drug use (J. Breath Res. 10.1088/1752-7163/ab35fd).

“There are a few ways we think this could impact society,” says Cristina Davis, who led the research along with Michael Schivo from the UC Davis Medical Center.

Patients suffering chronic pain are commonly prescribed opioids and other analgesic drugs. Monitoring opioids and their metabolites in such patients is important to ensure that they are taking their drugs correctly, the prescribed drugs are being metabolized properly and that they are not taking any confounding medication. Blood testing is the gold standard for this, but it is invasive and requires specialized personnel to collect. Breath testing could provide a reliable, easily available and non-invasive alternative.

In this study, the researchers used a simple and non-invasive technique to collect exhaled breath condensate (EBC) from a small group of chronic pain patients at the UC Davis Medical Center. The patients received infusions of pain medication including morphine and hydromorphone, or oral doses of oxycodone.

The patients were asked to breathe normally for 15 min into a specialized collection device: a glass tube surrounded by dry ice. The droplets in breath condense and are stored in a freezer until testing. The researchers also washed the collection device with an ethanol solvent after EBC extraction to retrieve any compounds stuck to the glass surface. They analysed all of the samples using liquid chromatography coupled to mass spectrometry to identify metabolites present in the sample and  quantify the drugs being used.

After each EBC collection, blood samples were taken immediately, enabling the researchers to compare opioids and metabolites in breath with levels in blood samples and with the delivered doses. “We can see both the original drug and metabolites in exhaled breath,” Davis explains.

In this pilot study, the researchers were able to detect, quantify and identify several opioid metabolites in EBC and the subsequent ethanol solvent wash. This confirms that infused opioid drugs are present in exhaled breath, albeit in low amounts. They also found promising correlations between concentrations in blood and breath for some of the main opioids and their metabolites.

Davis notes that fully validating this breath test will require more data from larger groups of patients. Her team is now working towards real-time, bedside testing.

Right now this “breath test” is too cumbersome and takes too long ( 15 minutes ) … but… as with everything else… it becomes miniaturized and “shorter test time”… can you see cops with every traffic stop that drivers are subjected to performing this test…  To confirm the cop’s suspicion of “driving under the influence “… will any trace of opiates in such breath test start resulting in all sorts of arrests and charges against anyone legally taking a controlled substance.

Could law enforcement do data mining in the state’s PMP and start using license plate readers to target people who are legally taking opiates. Just think of all the fines imposed and collected and all the assets and cash that could be confiscated using civil asset forfeiture laws.